|
Liver Cirrhosis
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
Hyperbiliverdinaemia (green jaundice) with green plasma and urine may be caused by a genetic defect in the BVR-A gene in conjunction with decompensated liver cirrhosis.
|
19580635 |
2009 |
|
Cirrhosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
FOXD2-AS1/miR-139-5p/BLVRA or CYTH2 axis might be the underlying molecular mechanism that dissects HCC development caused by cirrhosis.
|
31758243 |
2020 |
|
Obesity
|
0.010 |
Biomarker
|
disease |
BEFREE |
These data suggest that the reduction of BVR-A may be responsible for early alterations of the insulin signaling pathway in obesity and in this context may represent a novel molecular target to be investigated for the comprehension of the process of insulin resistance development in obesity.
|
30826467 |
2019 |
|
Aortic Aneurysm, Abdominal
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Unlike BLVRA mRNA level, the expression of HMOX1, HMOX1:BLVRA ratio and HO-1 protein level positively correlate with abdominal aortic aneurysm size in clinical samples.
|
31704097 |
2019 |
|
Non-alcoholic Fatty Liver Disease
|
0.010 |
Biomarker
|
disease |
BEFREE |
In conclusion, our data demonstrate a critical role for BVRA in protecting against lipid accumulation and oxidative stress in hepatocytes, which may serve as a future therapeutic target for NAFLD and its progression to NASH.
|
31422074 |
2019 |
|
Hyperbilirubinemia, Neonatal
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Moreover, individuals carrying the A-allele of G6PD 1388 G>A and BLVRA rs699512 had a significantly increased risk of developing neonatal hyperbilirubinaemia (OR = 5.01, P < 0.001, 95% CI: 3.42-7.85).
|
30636082 |
2019 |
|
Fatty Liver
|
0.010 |
Biomarker
|
disease |
BEFREE |
The antioxidant bilirubin and the enzyme that generates it, biliverdin reductase A (BVRA), are components of the heme catabolic pathway that have been shown to reduce hepatic steatosis.
|
29494209 |
2018 |
|
Pulmonary Emphysema
|
0.010 |
Biomarker
|
disease |
BEFREE |
In particular, x-ray computed tomography (CT) emphysema measurements are used to identify the most diseased and the second-most diseased lobes as BLVR targets.
|
29051040 |
2018 |
|
Steatohepatitis
|
0.010 |
Biomarker
|
disease |
BEFREE |
This review discusses the roles for bilirubin and BVRA in the prevention of steatosis, their functions in the later stages of liver disease, and their potential therapeutic application.
|
29494209 |
2018 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.010 |
Biomarker
|
disease |
BEFREE |
Therefore, Tat-mediated transduction of BLVRA may provide a potential tool to ameliorate β-cell deficit in pancreas with T2DM.
|
28198575 |
2017 |
|
Hyperbilirubinemia
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
The present study was undertaken to investigate the genotype and allele frequencies of the variants in the four bilirubin metabolism genes (UGT1A1, OATP2, HMOX1, and BLVRA) and their association with hyperbilirubinemia.
|
27943244 |
2017 |
|
Childhood Hepatocellular Carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Predictive role BLVRA mRNA expression in hepatocellular cancer.
|
27740521 |
2017 |
|
Adult Hepatocellular Carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Predictive role BLVRA mRNA expression in hepatocellular cancer.
|
27740521 |
2017 |
|
Malignant neoplasm of liver
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Predictive role BLVRA mRNA expression in hepatocellular cancer.
|
27740521 |
2017 |
|
Liver carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
BLVRA mRNA levels in the liver as well as in PBL are significantly higher in HCC patients most likely as a feedback mechanism to control increased oxidative stress associated with HCC progression.
|
27740521 |
2017 |
|
Down Syndrome
|
0.010 |
Biomarker
|
disease |
BEFREE |
The above data support the hypothesis that the dysregulation of HO-1/BVR-A system contributes to the early increase of oxidative stress in DS and provide potential mechanistic paths involved in the neurodegenerative process and AD development.
|
25391381 |
2015 |
|
Kidney Diseases
|
0.010 |
Biomarker
|
group |
BEFREE |
In conclusion, the BVRA positive macrophage is a source of anti-inflammatory cytokine IL-10 in injured kidney, which may provide a potential target for treatment of kidney disease.
|
26393580 |
2015 |
|
Dermatologic disorders
|
0.010 |
Biomarker
|
group |
BEFREE |
Thus we suggested that Tat-BLVRA protein may provide an effective therapeutic agent for inflammatory skin diseases.
|
25239864 |
2015 |
|
Complete Trisomy 21 Syndrome
|
0.010 |
Biomarker
|
disease |
BEFREE |
The above data support the hypothesis that the dysregulation of HO-1/BVR-A system contributes to the early increase of oxidative stress in DS and provide potential mechanistic paths involved in the neurodegenerative process and AD development.
|
25391381 |
2015 |
|
Hepatitis C
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Compared to the controls, substantially increased BLVRA expression was detected in PBL (p<0.001) of therapeutically naïve HCV patients. mRNA levels of BLVRA in PBL closely correlated with those in liver tissue (r2 = 0.347,p = 0.03).
|
23536765 |
2013 |
|
Septicemia
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
We tested whether a highly polymorphic (GT)n microsatellite and single-nucleotide polymorphisms in HMOX1 and BLVRA/B genes are associated with outcome of sepsis.
|
23042203 |
2012 |
|
Sepsis
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
We tested whether a highly polymorphic (GT)n microsatellite and single-nucleotide polymorphisms in HMOX1 and BLVRA/B genes are associated with outcome of sepsis.
|
23042203 |
2012 |
|
Essential Hypertension
|
0.010 |
Biomarker
|
disease |
BEFREE |
These findings provide the first genetic evidence for the role of BLVRA on the susceptibility to human essential hypertension and blood pressure.
|
21721974 |
2011 |
|
Neurodegenerative Disorders
|
0.010 |
Biomarker
|
group |
BEFREE |
In conclusion, nitrosative stress-induced modifications on hippocampal BVR-A are an early event in the pathogenesis of AD since they appear also in MCI subjects and could contribute to the antioxidant and metabolic derangement characteristic of these neurodegenerative disorders.
|
21483094 |
2011 |
|
Coronary Artery Disease
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Four significant associations with CAD were detected after controlling age and the false discovery rate at 15%: the recessive effect of SNP rs887829 (UGT1A1 G-364A) [age-adjusted odds ratio (OR): 0.24; 95% confidence interval (CI): 0.10-0.60; P=0.0014] and dominant effect of rs4149013 (SLCO1B1 A-12099G) (age-adjusted OR: 0.70; 95% CI: 0.55-0.91; P=0.0069) on male CAD, and the additive effects of rs2877262 (BLVRA G+1238/in6C) (age-adjusted OR: 0.73; 95% CI: 0.59-0.89; P=0.0021) and rs2690381 (BLVRA G+2613/in6A) (age-adjusted OR: 0.70; 95% CI: 0.56-0.86; P=0.0008) on female CAD.
|
19238116 |
2009 |